Mycobacterium Tuberculosis Is Selectively Killed by Rifampin and Rifapentine in Hypoxia at Neutral PH

Overview

Journal Antimicrob Agents Chemother

Publisher American Society for Microbiology

Specialty Pharmacology

Date 2016 Dec 21

PMID 27993848

Citations 14

Authors

Angelo Iacobino

Giovanni Piccaro

Federico Giannoni

Alessandro Mustazzolu

Lanfranco Fattorini

Affiliations

Soon will be listed here.

Abstract

The activities of rifampin, rifapentine, bedaquiline, PA-824, clofazimine, nitazoxanide, isoniazid, amikacin, moxifloxacin, niclosamide, thioridazine, and pyrazinamide were tested against nonreplicating (dormant) H37Rv under conditions of hypoxia at pHs 5.8 and 7.3, mimicking environments of cellular granulomas and caseous granulomas, respectively. At pH 5.8, several drugs killed dormant bacilli, with the best being rifampin and rifapentine. At pH 7.3, only rifampin and rifapentine efficiently killed dormant bacilli, while all other drugs showed little activity.

Citing Articles

An O-methylflavone from Artemisia afra kills non-replicating hypoxic Mycobacterium tuberculosis.

Kellogg J, Alonso M, Jordan R, Xiao J, Cafiero J, Bush T J Ethnopharmacol. 2024; 333:118500.

PMID: 38944359 PMC: 11285045. DOI: 10.1016/j.jep.2024.118500.

Eradication of Drug-Tolerant 2022: Where We Stand.

Lanni A, Iacobino A, Fattorini L, Giannoni F Microorganisms. 2023; 11(6).

PMID: 37375013 PMC: 10301435. DOI: 10.3390/microorganisms11061511.

and Extracts Have Bactericidal Activity against in Physiologically Relevant Carbon Sources and Hypoxia.

Kiani B, Alonso M, Weathers P, Shell S Pathogens. 2023; 12(2).

PMID: 36839499 PMC: 9963027. DOI: 10.3390/pathogens12020227.

Molecular Mechanisms of MmpL3 Function and Inhibition.

Williams J, Abramovitch R Microb Drug Resist. 2023; 29(5):190-212.

PMID: 36809064 PMC: 10171966. DOI: 10.1089/mdr.2021.0424.

Challenges & Solutions for Recent Advancements in Multi-Drugs Resistance Tuberculosis: A Review.

Yadav P Microbiol Insights. 2023; 16:11786361231152438.

PMID: 36741475 PMC: 9893349. DOI: 10.1177/11786361231152438.

References

Lanoix J, Ioerger T, Ormond A, Kaya F, Sacchettini J, Dartois V . Selective Inactivity of Pyrazinamide against Tuberculosis in C3HeB/FeJ Mice Is Best Explained by Neutral pH of Caseum. Antimicrob Agents Chemother. 2015; 60(2):735-43. PMC: 4750710. DOI: 10.1128/AAC.01370-15. View

Getahun H, Matteelli A, Chaisson R, Raviglione M . Latent Mycobacterium tuberculosis infection. N Engl J Med. 2015; 372(22):2127-35. DOI: 10.1056/NEJMra1405427. View

Sarathy J, Zuccotto F, Hsinpin H, Sandberg L, Via L, Marriner G . Prediction of Drug Penetration in Tuberculosis Lesions. ACS Infect Dis. 2016; 2(8):552-63. PMC: 5028112. DOI: 10.1021/acsinfecdis.6b00051. View

Zumla A, Chakaya J, Centis R, DAmbrosio L, Mwaba P, Bates M . Tuberculosis treatment and management--an update on treatment regimens, trials, new drugs, and adjunct therapies. Lancet Respir Med. 2015; 3(3):220-34. DOI: 10.1016/S2213-2600(15)00063-6. View

Kahwati L, Feltner C, Halpern M, Woodell C, Boland E, Amick H . Primary Care Screening and Treatment for Latent Tuberculosis Infection in Adults: Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2016; 316(9):970-83. DOI: 10.1001/jama.2016.10357. View

Dartois V . The path of anti-tuberculosis drugs: from blood to lesions to mycobacterial cells. Nat Rev Microbiol. 2014; 12(3):159-67. PMC: 4341982. DOI: 10.1038/nrmicro3200. View

Wayne L, Hayes L . An in vitro model for sequential study of shiftdown of Mycobacterium tuberculosis through two stages of nonreplicating persistence. Infect Immun. 1996; 64(6):2062-9. PMC: 174037. DOI: 10.1128/iai.64.6.2062-2069.1996. View

Kim M, Wainwright H, Locketz M, Bekker L, Walther G, Dittrich C . Caseation of human tuberculosis granulomas correlates with elevated host lipid metabolism. EMBO Mol Med. 2010; 2(7):258-74. PMC: 2913288. DOI: 10.1002/emmm.201000079. View

Piccaro G, Giannoni F, Filippini P, Mustazzolu A, Fattorini L . Activities of drug combinations against Mycobacterium tuberculosis grown in aerobic and hypoxic acidic conditions. Antimicrob Agents Chemother. 2013; 57(3):1428-33. PMC: 3591868. DOI: 10.1128/AAC.02154-12. View

10.

Gengenbacher M, Kaufmann S . Mycobacterium tuberculosis: success through dormancy. FEMS Microbiol Rev. 2012; 36(3):514-32. PMC: 3319523. DOI: 10.1111/j.1574-6976.2012.00331.x. View

11.

Lenaerts A, Barry 3rd C, Dartois V . Heterogeneity in tuberculosis pathology, microenvironments and therapeutic responses. Immunol Rev. 2015; 264(1):288-307. PMC: 4368385. DOI: 10.1111/imr.12252. View

12.

Lanoix J, Lenaerts A, Nuermberger E . Heterogeneous disease progression and treatment response in a C3HeB/FeJ mouse model of tuberculosis. Dis Model Mech. 2015; 8(6):603-10. PMC: 4457036. DOI: 10.1242/dmm.019513. View

13.

Piccaro G, Poce G, Biava M, Giannoni F, Fattorini L . Activity of lipophilic and hydrophilic drugs against dormant and replicating Mycobacterium tuberculosis. J Antibiot (Tokyo). 2015; 68(11):711-4. DOI: 10.1038/ja.2015.52. View